Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported Q2 EPS of ($0.40), $0.04 better than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Contineum Therapeutics, Inc. (CTNM) click here.